Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if combination therapy with Pegylated Interferon
Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or
BMS-650032) for 24 weeks is effective and safe for treatment of Chronic Hepatitis C (CHC)
compared to current standard therapy with Pegylated Interferon Alpha-2a plus RBV for 48
weeks.